AbbVie Ends Rova-T Program as 3rd Lung Cancer Study Fails

AbbVie Ends Rova-T Program as 3rd Lung Cancer Study Fails - Nasdaq

- August 30, 2019

AbbVie Ends Rova-T Program as 3rd Lung Cancer Study Fails Nasdaq

AbbVie, Inc.ABBV announced that it is discontinuing development of its small-cell lung cancer (SCLC) candidate rovalpituzumab tesirine or Rova-T after failure ...

Search This Blog

Lung Cancer

AbbVie Ends Rova-T Program as 3rd Lung Cancer Study Fails - Nasdaq

Comments

Post a Comment

Popular posts from this blog

Beagles, other dogs could be used to help in early detection of lung cancers, study finds - Fox 32 Chicago

Not An Ordinary Cough: Lung Cancer Symptoms That You Might Neglect - International Business Times

Beagles, other dogs could be used to help in early detection of lung cancers, study finds - Fox 32 Chicago